Addressing CAR T-Cell Access Barriers in DLBCL

In this segment, Dr. Caron A. Jacobson discusses barriers that can prevent patients with diffuse large B-cell lymphoma (DLBCL) from accessing CAR T-cell therapy, particularly those who must travel long distances to specialized treatment centers. She highlights challenges such as unfamiliarity with urban environments, time away from work, lost income, family responsibilities, and the need for a caregiver to accompany the patient throughout treatment. Dr. Jacobson also discusses potential approaches to reducing the burden of travel, including virtual consultations, local arrangements for certain treatment-related procedures, and improved access to transportation, lodging, and caregiver support. She notes that changes to FDA requirements have reduced some of the logistical constraints associated with CAR T-cell therapy. NP Stefanie Sigmund reinforces the importance of identifying a reliable support person, while Dr. Mark Dailey observes that patients with stronger financial resources and family support may find it easier to navigate treatment. The discussion emphasizes the need for practical support strategies to improve equitable access to CAR T-cell therapy for patients with DLBCL.